GLUE

$10.631.21%-0.13

Pre-mercato: 10.75+0.12 +1.13%

Monte Rosa Therapeutics Inc (GLUE)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$10.76

Aprire:

$10.79

Volume 24 ore:

1,767,022

Volume relativo:

1.28

Capitalizzazione di mercato:

$906.88M

Reddito:

$42.95M

Utile/perdita netta:

-$130.01M

Rapporto P/E:

EPS:

-$1.63

Flusso di cassa netto:

-$19.66M

1W Prestazione:

-0.28%

1M Prestazione:

+1.24%

6M Prestazione:

-43.46%

1Y Prestazione:

-11.93%

Intervallo 1D:

$0.00$0.00

Intervallo di 1 settimana:

$10.40$11.20

Portata 52W:

$9.68$25.77

Profilo aziendale di Monte Rosa Therapeutics Inc (GLUE)

Nome

Monte Rosa Therapeutics Inc

Settore

Healthcare

Industria

Biotechnology

Telefono

617-949-2643

Indirizzo

321 HARRISON AVENUE, BOSTON, USA

Dipendente

150

Prossima data di guadagno

2026-11-05

Ultimi documenti SEC

SEC

Discussioni di GLUE su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Monte Rosa Therapeutics Inc Azioni (GLUE) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-10-01	Iniziato	H.C. Wainwright	Buy
2024-12-19	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-02-15	Iniziato	Wedbush	Outperform
2023-01-03	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-10-13	Iniziato	UBS	Buy
2022-08-15	Iniziato	Jefferies	Buy
2022-04-28	Iniziato	Credit Suisse	Neutral
2022-02-10	Iniziato	Wells Fargo	Equal Weight
2021-10-14	Iniziato	SVB Leerink	Mkt Perform

Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	123.67	75.62	0.00	0.00	0.00
Research and development USD (M)	141.50	121.56	111.27	85.06	57.16
Operating expenses USD (M)	177.88	156.73	143.31	112.38	72.88
Operating income USD (M)	-54.21	-81.11	-143.31	-112.38	-72.88
Income before tax USD (M)	-39.72	-70.13	-135.01	-108.50	-73.96
Income tax expense USD (M)	-1.10	2.57	0.34	-	-
Net income USD (M)	-38.63	-72.70	-135.35	-108.50	-73.96
Basic weighted shares shares (M)	83.07	73.91	51.40	47.23	-
Diluted weighted shares shares (M)	83.07	73.91	51.40	47.23	-

Monte Rosa Therapeutics Inc Azioni (GLUE) insider trading

Bowen MatthewOct 05 '26
Principal Accounting Officer
Transazione
Sale
Costo
$10.56
#Azioni
13
Valore ($)
137
#Azioni Totale
25,891
MARKUS WARMUTHJul 16 '26
Officer
Transazione
Proposed Sale
Costo
$23.18
#Azioni
9,500
Valore ($)
220,219
#Azioni Totale
0
Warmuth MarkusJul 16 '26
President & CEO
Transazione
Sale
Costo
$23.18
#Azioni
9,500
Valore ($)
220,219
#Azioni Totale
585,038
Champoux JenniferJul 15 '26
Chief Operating Officer
Transazione
Option Exercise
Costo
$3.98
#Azioni
4,351
Valore ($)
17,317
#Azioni Totale
66,722
Champoux JenniferJul 15 '26
Officer
Transazione
Proposed Sale
Costo
$23.38
#Azioni
4,351
Valore ($)
101,730
#Azioni Totale
0
Champoux JenniferJul 15 '26
Chief Operating Officer
Transazione
Sale
Costo
$23.38
#Azioni
4,351
Valore ($)
101,730
#Azioni Totale
62,371
Townson SharonJul 06 '26
Chief Scientific Officer
Transazione
Sale
Costo
$23.31
#Azioni
6,000
Valore ($)
139,849
#Azioni Totale
67,845
Townson SharonJul 06 '26
Chief Scientific Officer
Transazione
Option Exercise
Costo
$6.14
#Azioni
6,000
Valore ($)
36,840
#Azioni Totale
73,845
FILIP JANKUJun 30 '26
Officer
Transazione
Proposed Sale
Costo
$23.90
#Azioni
5,407
Valore ($)
129,227
#Azioni Totale
0
Janku FilipJun 30 '26
Chief Medical Officer
Transazione
Option Exercise
Costo
$13.41
#Azioni
5,407
Valore ($)
72,508
#Azioni Totale
66,019

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Bowen Matthew	Principal Accounting Officer	Oct 05 '26	Sale	$10.56	13	137	25,891
MARKUS WARMUTH	Officer	Jul 16 '26	Proposed Sale	$23.18	9,500	220,219	0
Warmuth Markus	President & CEO	Jul 16 '26	Sale	$23.18	9,500	220,219	585,038
Champoux Jennifer	Chief Operating Officer	Jul 15 '26	Option Exercise	$3.98	4,351	17,317	66,722
Champoux Jennifer	Officer	Jul 15 '26	Proposed Sale	$23.38	4,351	101,730	0
Champoux Jennifer	Chief Operating Officer	Jul 15 '26	Sale	$23.38	4,351	101,730	62,371
Townson Sharon	Chief Scientific Officer	Jul 06 '26	Sale	$23.31	6,000	139,849	67,845
Townson Sharon	Chief Scientific Officer	Jul 06 '26	Option Exercise	$6.14	6,000	36,840	73,845
FILIP JANKU	Officer	Jun 30 '26	Proposed Sale	$23.90	5,407	129,227	0
Janku Filip	Chief Medical Officer	Jun 30 '26	Option Exercise	$13.41	5,407	72,508	66,019

Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie

Nov 02, 2026

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Nov 02, 2026

Fort Technology Announces Receipt of Approval for a Voluntary Delisting of its Common Shares From the TSX Venture Exchange - The Manila Times

Nov 02, 2026

Oct 23, 2026

Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock? - Zacks Investment Research

Oct 23, 2026

Oct 22, 2026

189,430 Shares in Monte Rosa Therapeutics, Inc. $GLUE Purchased by Assenagon Asset Management S.A. - MarketBeat

Oct 22, 2026

Oct 16, 2026

Monte Rosa Therapeutics Stock Price Forecast. Should You Buy GLUE? - StockInvest.us

Oct 16, 2026

Oct 13, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat

Oct 13, 2026

Oct 05, 2026

Monte Rosa Therapeutics (NasdaqGS:GLUE) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 05, 2026

Oct 02, 2026

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada

Oct 02, 2026

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo

Oct 02, 2026

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Oct 02, 2026

Oct 01, 2026

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6% - What's Next? - MarketBeat

Oct 01, 2026

Monte Rosa Therapeutics Announces Positive Phase 1 Results for MRT-8102 in GFORCE-1 Trial - Kalkine Media

Oct 01, 2026